Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration.

Jones R. et al, (2023), Eye (Lond)

Developing decision support tools incorporating personalised predictions of likely visual benefit versus harm for cataract surgery: research programme

Sparrow JM. et al, (2022), Programme Grants for Applied Research, 10, 1 - 54

Assessing the impact of COVID-19 on visual acuity for diabetic macular edema patients treated with aflibercept in the UK

Scanlon PH. et al, (2022), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 63

The impact of COVID-19 on visual acuity for nAMD patients treated with aflibercept in the UK

Bailey C. et al, (2022), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 63

Improving the screening of risk factors in diabetic retinopathy.

Scanlon PH., (2022), Expert Rev Endocrinol Metab, 17, 235 - 243

Why Is Continued Vision Loss Still a Problem in Some Patients With Diabetic Retinopathy, Despite Treatment?

Bressler SB. et al, (2022), JAMA Ophthalmol, 140, 308 - 309

Should we still be performing macular laser for non-centre involving diabetic macular oedema? Results from a UK centre.

Scanlon PH. et al, (2022), Eye (Lond), 36, 646 - 648

Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years.

Talks SJ. et al, (2022), Eye (Lond), 36, 72 - 77

Diabetic retinopathy

Scanlon PH., (2022), Medicine (United Kingdom)

Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy

Prior L. et al, (2022), Eye (Basingstoke)

Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study.

Sivaprasad S. et al, (2021), Ophthalmology, 128, 1736 - 1747

Are there Still Indications for Macular Laser in Diabetic Macular Oedema?

Dale A. et al, (2021), EUROPEAN JOURNAL OF OPHTHALMOLOGY, 31, 8 - 8

Reply.

Lois N. and of the EMERALD Study Group None., (2021), Ophthalmology, 128, e46 - e47

Standardisation of Optical Coherence Tomography Angiography Imaging Biomarkers in Diabetic Retinal Disease.

Vujosevic S. et al, (2021), Ophthalmic Res

A Multitask Deep-Learning System to Classify Diabetic Macular Edema for Different Optical Coherence Tomography Devices: A Multicenter Analysis.

Tang F. et al, (2021), Diabetes Care

Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire.

Scanlon PH. et al, (2021), Acta Ophthalmol

Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study

Lois N. et al, (2021), Health Technology Assessment, 25, 1 - 104

Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort.

Smith JJ. et al, (2021), Br J Ophthalmol

Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy

Lois N. et al, (2021), Ophthalmology, 128, 561 - 573

The contribution of the English NHS Diabetic Eye Screening Programme to reductions in diabetes-related blindness, comparisons within Europe, and future challenges.

Scanlon PH., (2021), Acta Diabetol, 58, 521 - 530

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?